Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Recruiting 3Completed 3Terminated 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × alectinib × Clear all
NCT02521051 2025-05-13

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

Massachusetts General Hospital

Phase 1/2 Terminated
11 enrolled 21 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03131206 2021-09-27

A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Dana-Farber Cancer Institute

Phase 1/2 Terminated
5 enrolled 8 charts
Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡